Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM-AHF trial of intravenous ferric carboxymaltose in acute heart failure with iron deficiency
MOH_2017-06-01_000408Phase 4Not yet recruiting
- Sponsor
- CSL Vifor
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Acute Heart Failure (AHF) and iron deficiency anemia (IDA) comparing Intravenous Ferinject with Intravenous placebo (2 arms). Primary endpoint: Recurrent heart failure hospitalizations and cardiovascular death. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
Acute Heart Failure (AHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on MOH_2017-06-01_000408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-01_000408.